Fortune Venture Capital logo

Fortune Venture Capital

Asia, Guangdong, China, Shenzhen

Description

Fortune Venture Capital, widely recognized as Shenzhen Capital Group Co., Ltd. (SCGC), stands as a cornerstone of China's venture capital landscape, having been established in April 2000 as one of the nation's earliest market-oriented VC firms. Headquartered in Shenzhen, SCGC has evolved into a dominant force, characterized by its extensive capital base and a broad investment mandate that spans the full life cycle of enterprises, from nascent startups to mature, pre-IPO companies.

The firm's investment strategy is highly diversified, targeting a wide array of high-growth sectors critical to China's economic transformation. These include cutting-edge fields such as information technology, new materials, biomedicine, new energy, environmental protection, high-end equipment manufacturing, and modern services. This comprehensive sectoral approach enables SCGC to identify and back innovative companies across various stages of development, contributing significantly to the advancement of strategic emerging industries.

SCGC's operational scale is truly impressive. As of 2023, the firm manages a substantial portfolio across 256 funds, with total assets under management (AUM) exceeding RMB 470 billion, which translates to approximately USD 65 billion. This immense financial capacity underpins their ability to make significant investments. Their active and prolific investment approach has resulted in backing over 1,800 companies, demonstrating their deep market penetration and commitment to fostering entrepreneurial growth.

A key indicator of SCGC's success is its remarkable track record of exits. To date, 271 of their portfolio companies have successfully gone public through initial public offerings (IPOs), solidifying their reputation for identifying and nurturing ventures with high potential for market realization. While specific initial check sizes can vary based on the stage and sector, SCGC typically deploys substantial capital, with first cheques generally ranging from approximately $1 million for early-stage ventures to over $100 million for more mature, growth-stage companies, reflecting their comprehensive investment scope.

Investor Profile

Fortune Venture Capital has backed more than 47 startups, with 24 new investments in the last 12 months alone. The firm has led 17 rounds, about 36% of its total and boasts 45 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Series A, Seed rounds (top funding stages).
  • Majority of deals are located in China, United States, United Kingdom.
  • Strong thematic focus on Manufacturing, Biotechnology, Advanced Materials.
  • Led 11 rounds in the past year.
  • Typical check size: $1M – $100M.

Stage Focus

  • Series B (30%)
  • Series A (28%)
  • Seed (15%)
  • Series C (11%)
  • Series Unknown (11%)
  • Series D (4%)
  • Angel (2%)

Country Focus

  • China (94%)
  • United States (2%)
  • United Kingdom (2%)

Industry Focus

  • Manufacturing
  • Biotechnology
  • Advanced Materials
  • Software
  • Medical
  • Industrial Manufacturing
  • Medical Device
  • Biopharma
  • Chemical
  • Health Care
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Fortune Venture Capital frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 2
Shunwei Capital
Asia, Beijing, China, Beijing
Co-Investments: 3
The Hina Group
North America, California, United States, San Francisco
Co-Investments: 3
Legend Capital
Asia, Beijing, China, Beijing
Co-Investments: 3
Temasek Holdings
Asia, Central Region, Singapore, Singapore
Co-Investments: 2
Qiming Venture Partners
Asia, Shanghai, China, Shanghai
Co-Investments: 3
Shenzhen Capital Group
Asia, Hunan, China, Nanshan
Co-Investments: 2
GGV Capital
North America, California, United States, Menlo Park
Co-Investments: 2
Intel Capital
North America, California, United States, Santa Clara
Co-Investments: 2

What are some of recent deals done by Fortune Venture Capital?

Duochang Tech develops ultra-precision piezoelectric motion systems and extreme environment testing equipment.

AerospaceIndustrial AutomationRobotics
Series ASep 15, 2025
AIsphere

Beijing, Beijing, China

AIsphere focuses on visual multimodal large models and empowering content producers in many sectors and scenarios with AIGC technology.

Artificial Intelligence (AI)Computer VisionService Industry
Series BSep 10, 2025
Amount Raised: $60,000,000
Hongde New Materials

Ningbo, Zhejiang, China

Hongde New Materials produces thermoplastic composite materials with fiber reinforcement.

Advanced MaterialsBuilding MaterialManufacturing
Series ASep 8, 2025
Silicon Integrated

Wuhan, Hubei, China

Silicon Integrated offers mixed-signal chips.

Application Specific Integrated Circuit (ASIC)ElectronicsManufacturing
Series DAug 13, 2025
Vita Dynamics

Beijing, Beijing, China

Vita Dynamics aims to develop robots based on the concept of embodied intelligence.

Artificial Intelligence (AI)Robotic Process Automation (RPA)Robotics
AngelAug 7, 2025
Xinjie Energy

Shenzhen, Guangdong, China

Xinjie Energy specializes in the research, development, and production of lithium metal solid-state batteries.

BatteryEnergy StorageRenewable Energy
Series AAug 7, 2025
ENGINEAI

Shenzhen, Guangdong, China

ENGINEAI specializes in providing artificial intelligence solutions and data analytics services for businesses.

AnalyticsArtificial Intelligence (AI)Robotic Process Automation (RPA)Robotics
Series AJul 21, 2025
Amount Raised: $139,291,286
Deep Robotics

Hangzhou, Zhejiang, China

Deep Robotics develops and manufactures embodied‑AI robots, focusing on quadrupedal, wheeled‑legged, and humanoid platforms.

Artificial Intelligence (AI)Machinery ManufacturingManufacturingRobotics
Series UnknownJul 7, 2025
Amount Raised: $69,710,701
Sungen Biomedical

Daxing, Beijing, China

Sungen Biomedical is engaged in the development of first-in-class (FIC) antibody therapeutics.

BiopharmaHealth CareMedical
Series AMay 30, 2025
Amount Raised: $41,688,090
Chenglian Technology

Nanjing, Jiangsu, China

Chenglian Technology is a high-tech enterprise that focuses on the digital manufacturing of the whole process of dentistry.

3D PrintingDentalManufacturingMedical Device
Series BMay 27, 2025
Amount Raised: $27,822,216